Overview
Methylazoxymethanol (abbreviated MAM) is a low‑molecular‑weight organic compound that functions as a potent alkylating agent and a known carcinogen. Chemically, it is the methylated derivative of azoxymethanol and is classified as a nitroso compound. MAM is primarily recognized for its use in biomedical research as a tumor‑inducing agent and as a neurotoxicant in experimental models.
Chemical Data
| Property | Value |
|---|---|
| IUPAC name | (1‑methylazoxymethyl)oxymethanol |
| Synonyms | MAM; 1‑Methyl‑2‑azoxy‑acetaldehyde; N‑Methyl‑azoxy‑methanol |
| Molecular formula | C₃H₇NO₂ |
| Molar mass | 89.09 g mol⁻¹ |
| SMILES | CN+[O-]COC=O |
| Physical state | Liquid at room temperature |
| Solubility | Miscible with water and most organic solvents |
| Stability | Decomposes upon prolonged exposure to heat, light, or alkaline conditions, releasing formaldehyde and other volatile products |
Synthesis and Metabolism
Methylazoxymethanol is not typically synthesized for commercial use; instead, it is generated in situ by the metabolic reduction of the carcinogen azoxymethane (AOM) or by enzymatic cleavage of certain plant‑derived nitrosamines. In the body, MAM undergoes rapid hydrolysis to produce methyldiazonium ion, a highly reactive electrophile that methylates nucleophilic sites in DNA, RNA, and proteins. This methylation underlies its genotoxic and carcinogenic properties.
Biological Activity
-
Carcinogenicity
- MAM is classified by the International Agency for Research on Cancer (IARC) as a probable human carcinogen (Group 2A) based on animal studies.
- Administration of MAM to rodents induces a spectrum of tumors, most notably in the colon, brain, and pancreas, making it a valuable tool for studying the molecular mechanisms of cancer initiation and progression.
-
Neurotoxicity
- In neonatal rodents, systemic exposure to MAM produces selective loss of proliferating neuronal precursors, leading to cortical malformations that model human cortical dysplasia and certain forms of epilepsy.
- The neurotoxic phenotype is dose‑dependent and typically requires a single intraperitoneal injection at post‑natal day 0–2.
-
Experimental Applications
- Carcinogenesis models: MAM/azoxymethane protocols are standard for inducing colonic adenomas in mice and rats, facilitating the evaluation of chemopreventive agents.
- Neurodevelopmental research: The “MAM model” of cortical malformation is employed to investigate neuronal migration, synaptic connectivity, and seizure susceptibility.
- Methylation studies: Because the methyldiazonium ion preferentially methylates O⁶‑guanine in DNA, MAM serves as a probe for studying DNA repair pathways, particularly O⁶‑alkylguanine‑DNA alkyltransferase (AGT).
Toxicology and Safety
- Acute toxicity: The LD₅₀ (oral, rat) is reported in the range of 30–50 mg kg⁻¹. Symptoms of acute exposure include gastrointestinal distress, hematopoietic suppression, and central nervous system depression.
- Chronic exposure: Repeated low‑dose exposure leads to cumulative DNA damage and an elevated incidence of neoplasia.
- Protective measures: Handling of MAM requires a certified chemical fume hood, personal protective equipment (gloves, lab coat, eye protection), and adherence to institutional biosafety protocols. Waste disposal must follow regulations for hazardous alkylating agents.
Regulatory Status
- United States: Listed under the Toxic Substances Control Act (TSCA) as a regulated hazardous chemical.
- European Union: Classified under the EU CLP regulation as H350 (May cause cancer) and H410 (Very toxic to aquatic life with long‑lasting effects).
- Occupational exposure limits: No specific permissible exposure limit (PEL) is established; however, many institutions adopt the most restrictive guidelines for similar nitroso compounds (e.g., ≤0.1 ppm time‑weighted average).
Research Considerations
- Dose selection: Because the biological effects of MAM are steeply dose‑dependent, precise dosing (often based on body weight) is essential for reproducibility.
- Timing of administration: In neurodevelopmental studies, the critical window for inducing cortical malformations is restricted to the early post‑natal period; adult exposure typically results in systemic toxicity without the same pattern of neuronal loss.
- Control of confounding variables: The instability of MAM in aqueous solutions necessitates freshly prepared dosing solutions and rapid administration to avoid degradation products that have different toxicological profiles.
References (selected)
- International Agency for Research on Cancer (IARC). Methylazoxymethanol – Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 100F, 2012.
- Koh, J. Y. et al. “Methylazoxymethanol-induced cortical dysplasia as a model for developmental brain disorders.” Neuroscience 312 (2015): 1‑12.
- Rao, C. V. et al. “Azoxymethane and methylazoxymethanol in experimental colon carcinogenesis.” Carcinogenesis 20, no. 5 (1999): 759‑764.
This entry summarizes established, peer‑reviewed knowledge about methylazoxymethanol as of the latest available scientific literature. No speculative or unverified information is included.
